Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cardonilizumab with or without HAIC as neoadjuvant therapy before hepatectomy for multinodular hepatocellular carcinoma
ChiCTR2200067161Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of Guangxi Medical University
- Start
- Dec 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cadonilimab in hepatocellular carcinoma (HCC) (3 arms), sponsored by The First Affiliated Hospital of Guangxi Medical University. Primary endpoints: Major pathologic response, 1-year event-free survival and 1 more. Started Dec 2022; status: recruiting.
02
Drugs
cadonilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2200067161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200067161.